CTXR SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Feb 13, 2026

10-K/A

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Jan 28, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Dec 23, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Citius Oncology Presents Positive Quality of Life Data for LYMPHIR® in Cutaneous T-Cell Lymphoma at EORTC-CLTG Congress

Nov 4, 2026

8-K

Citius Oncology Reports 120% Growth in LYMPHIR® Wholesaler Shipments for Q4 Fiscal 2026

Oct 26, 2026

8-K

Citius Pharmaceuticals Granted Nasdaq Bid Price Compliance Extension

Aug 21, 2026

8-K

Citius Pharmaceuticals Reports Fiscal Third Quarter 2026 Financial Results and Business Update

Aug 14, 2026

8-K

Citius Oncology Reports Strong Commercial Momentum for LYMPHIR Cancer Treatment

Aug 5, 2026

8-K

Citius Oncology Reports Positive Phase 1 Data for LYMPHIR® in Combination with Pembrolizumab for Gynecologic Malignancies

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Apr 24, 2026

424B5

REGISTERED OFFERING

Oct 21, 2025

424B5

REGISTERED OFFERING

Jun 11, 2025

424B5

REGISTERED OFFERING

Apr 2, 2025

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Jan 8, 2025

424B5

Nov 18, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

May 22, 2026

S-3

SHELF | Offering amount: $250,000,000.00 EFFECTIVE

Feb 23, 2024

S-8

Registration

Feb 23, 2024

S-8

Registration

Feb 10, 2023

POS AM

1,622,989 Shares of Common Stock Issuable upon Exercise of Warrants EFFECTIVE

Jul 2, 2021

S-8

Registration

Jun 22, 2021

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

CVI Investments, Inc. (Filed by)

Aug 14, 2026

SCHEDULE 13D/A

Citius Pharmaceuticals, Inc. (Filed by)

Jun 4, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

May 22, 2026

SCHEDULE 13G/A

CVI Investments, Inc. (Filed by)

Feb 17, 2026

SCHEDULE 13D/A

Citius Pharmaceuticals, Inc. (Filed by)

Dec 17, 2025

SCHEDULE 13G

CVI Investments, Inc. (Filed by)

Oct 27, 2025

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Aug 10, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 3, 2026

CORRESP

Form CORRESP - Correspondence

May 29, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 4, 2024

CORRESP

Form CORRESP - Correspondence

Feb 29, 2024

LETTER

Form UPLOAD - SEC-generated letter

Feb 29, 2024

Citius Pharmaceuticals, Inc. CTXR · SEC Filings